NASDAQ: CRSP · Life Sciences · 9 alerts · CIK 1674416
Share price
$40.37Close, Nov 16
Market cap
$3.92B
Shares outstanding
97MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Crispr Therapeutics AG filings on SEC EDGAR ↗
Crispr Therapeutics CEO Samarth Kulkarni Sells $2.38M of Stock
Samarth Kulkarni, CEO, sold 47,837 shares of Crispr Therapeutics AG at $49.78 a share, worth $2.38M in total on Oct 19, 2026. Shares held after the trade: 311,899 (-13.3%).
Crispr Therapeutics Director Simeon George Sells $720K of Stock
Simeon George, Director, sold 14,514 shares of Crispr Therapeutics AG at $49.63 a share, worth $720K in total on Oct 14, 2026. Shares held after the trade: 15,486 (-48.4%).
Crispr Therapeutics General Counsel and Secretary James R. Kasinger Sells $51.2K of Stock
James R. Kasinger, General Counsel and Secretary, sold 1,040 shares of Crispr Therapeutics AG at $49.26 a share, worth $51.2K in total on Oct 14, 2026. Shares held after the trade: 95,857 (-1.1%).
Crispr Therapeutics CEO Samarth Kulkarni Sells $202K of Stock
Samarth Kulkarni, CEO, sold 4,098 shares of Crispr Therapeutics AG at $49.26 a share, worth $202K in total on Oct 14, 2026. Shares held after the trade: 259,736 (-1.6%).
Crispr Therapeutics General Counsel and Secretary James R. Kasinger Sells $119K of Stock
James R. Kasinger, General Counsel and Secretary, sold 1,990 shares of Crispr Therapeutics AG at $60.04 a share, worth $119K in total on Oct 6, 2026. Shares held after the trade: 94,784 (-2.1%).
Crispr Therapeutics General Counsel and Secretary James R. Kasinger Sells $626K of Stock
James R. Kasinger, General Counsel and Secretary, sold 10,400 shares of Crispr Therapeutics AG at $60.24 a share, worth $626K in total on Sep 22, 2026. Shares held after the trade: 94,784 (-9.9%).
Crispr Therapeutics Director Ali Behbahani Sells $781K of Stock
Ali Behbahani, Director, sold 13,679 shares of Crispr Therapeutics AG at $57.09 a share, worth $781K in total on Sep 17, 2026. Shares held after the trade: 16,637 (-45.1%).